Global Psychedelic Drugs Market Insights, Forecast to 2029
This report presents an overview of global market for Psychedelic Drugs market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Psychedelic Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Psychedelic Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Psychedelic Drugs revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Psychedelic Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Psychedelic Drugs revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including COMPASS Pathways PLC, Pfizer, Eli Lilly, GlaxoSmithKline, Cybin Inc, Field Trip Health, ATAI Life Sciences, NUMINUS WELLNESS and MindMed, etc.
By Company
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Psychedelic Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Psychedelic Drugs companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Psychedelic Drugs revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
This report researches the key producers of Psychedelic Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Psychedelic Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Psychedelic Drugs revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Psychedelic Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Psychedelic Drugs revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including COMPASS Pathways PLC, Pfizer, Eli Lilly, GlaxoSmithKline, Cybin Inc, Field Trip Health, ATAI Life Sciences, NUMINUS WELLNESS and MindMed, etc.
By Company
- COMPASS Pathways PLC
- Pfizer
- Eli Lilly
- GlaxoSmithKline
- Cybin Inc
- Field Trip Health
- ATAI Life Sciences
- NUMINUS WELLNESS
- MindMed
- HAVN Life Sciences
- Seelos Therapeutics
- Jannsen
- Acadia Pharmaceuticals
- Intellipharmaceutics
- Revive Therapeutics
- Mydecine Innovations Group
- Red Light Holland
- Braxia Scientific
- Mind Cure Health
- Entheon Biomedical
- Psilocybin
- LSD
- MDMA
- DMT
- Ketamine
- Others
- Depressive Disorders
- Post-Traumatic Stress Disorders
- Substance Abuse Disorders
- Obsessive Compulsive Disorders
- Others
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East, Africa, and Latin America
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Psychedelic Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Psychedelic Drugs companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Psychedelic Drugs revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Psychedelic Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Psilocybin
1.2.3 LSD
1.2.4 MDMA
1.2.5 DMT
1.2.6 Ketamine
1.2.7 Others
1.3 Market by Application
1.3.1 Global Psychedelic Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Depressive Disorders
1.3.3 Post-Traumatic Stress Disorders
1.3.4 Substance Abuse Disorders
1.3.5 Obsessive Compulsive Disorders
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Psychedelic Drugs Market Perspective (2018-2029)
2.2 Global Psychedelic Drugs Growth Trends by Region
2.2.1 Psychedelic Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Psychedelic Drugs Historic Market Size by Region (2018-2023)
2.2.3 Psychedelic Drugs Forecasted Market Size by Region (2024-2029)
2.3 Psychedelic Drugs Market Dynamics
2.3.1 Psychedelic Drugs Industry Trends
2.3.2 Psychedelic Drugs Market Drivers
2.3.3 Psychedelic Drugs Market Challenges
2.3.4 Psychedelic Drugs Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Revenue Psychedelic Drugs by Players
3.1.1 Global Psychedelic Drugs Revenue by Players (2018-2023)
3.1.2 Global Psychedelic Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Psychedelic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Psychedelic Drugs, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Psychedelic Drugs Market Concentration Ratio
3.4.1 Global Psychedelic Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Psychedelic Drugs Revenue in 2022
3.5 Global Key Players of Psychedelic Drugs Head office and Area Served
3.6 Global Key Players of Psychedelic Drugs, Product and Application
3.7 Global Key Players of Psychedelic Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 PSYCHEDELIC DRUGS BREAKDOWN DATA BY TYPE
4.1 Global Psychedelic Drugs Historic Market Size by Type (2018-2023)
4.2 Global Psychedelic Drugs Forecasted Market Size by Type (2024-2029)
5 PSYCHEDELIC DRUGS BREAKDOWN DATA BY APPLICATION
5.1 Global Psychedelic Drugs Historic Market Size by Application (2018-2023)
5.2 Global Psychedelic Drugs Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Psychedelic Drugs Market Size (2018-2029)
6.2 North America Psychedelic Drugs Market Size by Type
6.2.1 North America Psychedelic Drugs Market Size by Type (2018-2023)
6.2.2 North America Psychedelic Drugs Market Size by Type (2024-2029)
6.2.3 North America Psychedelic Drugs Market Share by Type (2018-2029)
6.3 North America Psychedelic Drugs Market Size by Application
6.3.1 North America Psychedelic Drugs Market Size by Application (2018-2023)
6.3.2 North America Psychedelic Drugs Market Size by Application (2024-2029)
6.3.3 North America Psychedelic Drugs Market Share by Application (2018-2029)
6.4 North America Psychedelic Drugs Market Size by Country
6.4.1 North America Psychedelic Drugs Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Psychedelic Drugs Market Size by Country (2018-2023)
6.4.3 North America Psychedelic Drugs Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 EUROPE
7.1 Europe Psychedelic Drugs Market Size (2018-2029)
7.2 Europe Psychedelic Drugs Market Size by Type
7.2.1 Europe Psychedelic Drugs Market Size by Type (2018-2023)
7.2.2 Europe Psychedelic Drugs Market Size by Type (2024-2029)
7.2.3 Europe Psychedelic Drugs Market Share by Type (2018-2029)
7.3 Europe Psychedelic Drugs Market Size by Application
7.3.1 Europe Psychedelic Drugs Market Size by Application (2018-2023)
7.3.2 Europe Psychedelic Drugs Market Size by Application (2024-2029)
7.3.3 Europe Psychedelic Drugs Market Share by Application (2018-2029)
7.4 Europe Psychedelic Drugs Market Size by Country
7.4.1 Europe Psychedelic Drugs Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Psychedelic Drugs Market Size by Country (2018-2023)
7.4.3 Europe Psychedelic Drugs Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 CHINA
8.1 China Psychedelic Drugs Market Size (2018-2029)
8.2 China Psychedelic Drugs Market Size by Type
8.2.1 China Psychedelic Drugs Market Size by Type (2018-2023)
8.2.2 China Psychedelic Drugs Market Size by Type (2024-2029)
8.2.3 China Psychedelic Drugs Market Share by Type (2018-2029)
8.3 China Psychedelic Drugs Market Size by Application
8.3.1 China Psychedelic Drugs Market Size by Application (2018-2023)
8.3.2 China Psychedelic Drugs Market Size by Application (2024-2029)
8.3.3 China Psychedelic Drugs Market Share by Application (2018-2029)
9 ASIA (EXCLUDING CHINA)
9.1 Asia Psychedelic Drugs Market Size (2018-2029)
9.2 Asia Psychedelic Drugs Market Size by Type
9.2.1 Asia Psychedelic Drugs Market Size by Type (2018-2023)
9.2.2 Asia Psychedelic Drugs Market Size by Type (2024-2029)
9.2.3 Asia Psychedelic Drugs Market Share by Type (2018-2029)
9.3 Asia Psychedelic Drugs Market Size by Application
9.3.1 Asia Psychedelic Drugs Market Size by Application (2018-2023)
9.3.2 Asia Psychedelic Drugs Market Size by Application (2024-2029)
9.3.3 Asia Psychedelic Drugs Market Share by Application (2018-2029)
9.4 Asia Psychedelic Drugs Market Size by Region
9.4.1 Asia Psychedelic Drugs Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Psychedelic Drugs Market Size by Region (2018-2023)
9.4.3 Asia Psychedelic Drugs Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 MIDDLE EAST, AFRICA, AND LATIN AMERICA
10.1 Middle East, Africa, and Latin America Psychedelic Drugs Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Type
10.2.1 Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Psychedelic Drugs Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Application
10.3.1 Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Psychedelic Drugs Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Country
10.4.1 Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 KEY PLAYERS PROFILES
11.1 COMPASS Pathways PLC
11.1.1 COMPASS Pathways PLC Company Details
11.1.2 COMPASS Pathways PLC Business Overview
11.1.3 COMPASS Pathways PLC Psychedelic Drugs Introduction
11.1.4 COMPASS Pathways PLC Revenue in Psychedelic Drugs Business (2018-2023)
11.1.5 COMPASS Pathways PLC Recent Developments
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Psychedelic Drugs Introduction
11.2.4 Pfizer Revenue in Psychedelic Drugs Business (2018-2023)
11.2.5 Pfizer Recent Developments
11.3 Eli Lilly
11.3.1 Eli Lilly Company Details
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly Psychedelic Drugs Introduction
11.3.4 Eli Lilly Revenue in Psychedelic Drugs Business (2018-2023)
11.3.5 Eli Lilly Recent Developments
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Details
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Psychedelic Drugs Introduction
11.4.4 GlaxoSmithKline Revenue in Psychedelic Drugs Business (2018-2023)
11.4.5 GlaxoSmithKline Recent Developments
11.5 Cybin Inc
11.5.1 Cybin Inc Company Details
11.5.2 Cybin Inc Business Overview
11.5.3 Cybin Inc Psychedelic Drugs Introduction
11.5.4 Cybin Inc Revenue in Psychedelic Drugs Business (2018-2023)
11.5.5 Cybin Inc Recent Developments
11.6 Field Trip Health
11.6.1 Field Trip Health Company Details
11.6.2 Field Trip Health Business Overview
11.6.3 Field Trip Health Psychedelic Drugs Introduction
11.6.4 Field Trip Health Revenue in Psychedelic Drugs Business (2018-2023)
11.6.5 Field Trip Health Recent Developments
11.7 ATAI Life Sciences
11.7.1 ATAI Life Sciences Company Details
11.7.2 ATAI Life Sciences Business Overview
11.7.3 ATAI Life Sciences Psychedelic Drugs Introduction
11.7.4 ATAI Life Sciences Revenue in Psychedelic Drugs Business (2018-2023)
11.7.5 ATAI Life Sciences Recent Developments
11.8 NUMINUS WELLNESS
11.8.1 NUMINUS WELLNESS Company Details
11.8.2 NUMINUS WELLNESS Business Overview
11.8.3 NUMINUS WELLNESS Psychedelic Drugs Introduction
11.8.4 NUMINUS WELLNESS Revenue in Psychedelic Drugs Business (2018-2023)
11.8.5 NUMINUS WELLNESS Recent Developments
11.9 MindMed
11.9.1 MindMed Company Details
11.9.2 MindMed Business Overview
11.9.3 MindMed Psychedelic Drugs Introduction
11.9.4 MindMed Revenue in Psychedelic Drugs Business (2018-2023)
11.9.5 MindMed Recent Developments
11.10 HAVN Life Sciences
11.10.1 HAVN Life Sciences Company Details
11.10.2 HAVN Life Sciences Business Overview
11.10.3 HAVN Life Sciences Psychedelic Drugs Introduction
11.10.4 HAVN Life Sciences Revenue in Psychedelic Drugs Business (2018-2023)
11.10.5 HAVN Life Sciences Recent Developments
11.11 Seelos Therapeutics
11.11.1 Seelos Therapeutics Company Details
11.11.2 Seelos Therapeutics Business Overview
11.11.3 Seelos Therapeutics Psychedelic Drugs Introduction
11.11.4 Seelos Therapeutics Revenue in Psychedelic Drugs Business (2018-2023)
11.11.5 Seelos Therapeutics Recent Developments
11.12 Jannsen
11.12.1 Jannsen Company Details
11.12.2 Jannsen Business Overview
11.12.3 Jannsen Psychedelic Drugs Introduction
11.12.4 Jannsen Revenue in Psychedelic Drugs Business (2018-2023)
11.12.5 Jannsen Recent Developments
11.13 Acadia Pharmaceuticals
11.13.1 Acadia Pharmaceuticals Company Details
11.13.2 Acadia Pharmaceuticals Business Overview
11.13.3 Acadia Pharmaceuticals Psychedelic Drugs Introduction
11.13.4 Acadia Pharmaceuticals Revenue in Psychedelic Drugs Business (2018-2023)
11.13.5 Acadia Pharmaceuticals Recent Developments
11.14 Intellipharmaceutics
11.14.1 Intellipharmaceutics Company Details
11.14.2 Intellipharmaceutics Business Overview
11.14.3 Intellipharmaceutics Psychedelic Drugs Introduction
11.14.4 Intellipharmaceutics Revenue in Psychedelic Drugs Business (2018-2023)
11.14.5 Intellipharmaceutics Recent Developments
11.15 Revive Therapeutics
11.15.1 Revive Therapeutics Company Details
11.15.2 Revive Therapeutics Business Overview
11.15.3 Revive Therapeutics Psychedelic Drugs Introduction
11.15.4 Revive Therapeutics Revenue in Psychedelic Drugs Business (2018-2023)
11.15.5 Revive Therapeutics Recent Developments
11.16 Mydecine Innovations Group
11.16.1 Mydecine Innovations Group Company Details
11.16.2 Mydecine Innovations Group Business Overview
11.16.3 Mydecine Innovations Group Psychedelic Drugs Introduction
11.16.4 Mydecine Innovations Group Revenue in Psychedelic Drugs Business (2018-2023)
11.16.5 Mydecine Innovations Group Recent Developments
11.17 Red Light Holland
11.17.1 Red Light Holland Company Details
11.17.2 Red Light Holland Business Overview
11.17.3 Red Light Holland Psychedelic Drugs Introduction
11.17.4 Red Light Holland Revenue in Psychedelic Drugs Business (2018-2023)
11.17.5 Red Light Holland Recent Developments
11.18 Braxia Scientific
11.18.1 Braxia Scientific Company Details
11.18.2 Braxia Scientific Business Overview
11.18.3 Braxia Scientific Psychedelic Drugs Introduction
11.18.4 Braxia Scientific Revenue in Psychedelic Drugs Business (2018-2023)
11.18.5 Braxia Scientific Recent Developments
11.19 Mind Cure Health
11.19.1 Mind Cure Health Company Details
11.19.2 Mind Cure Health Business Overview
11.19.3 Mind Cure Health Psychedelic Drugs Introduction
11.19.4 Mind Cure Health Revenue in Psychedelic Drugs Business (2018-2023)
11.19.5 Mind Cure Health Recent Developments
11.20 Entheon Biomedical
11.20.1 Entheon Biomedical Company Details
11.20.2 Entheon Biomedical Business Overview
11.20.3 Entheon Biomedical Psychedelic Drugs Introduction
11.20.4 Entheon Biomedical Revenue in Psychedelic Drugs Business (2018-2023)
11.20.5 Entheon Biomedical Recent Developments
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Psychedelic Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Psilocybin
1.2.3 LSD
1.2.4 MDMA
1.2.5 DMT
1.2.6 Ketamine
1.2.7 Others
1.3 Market by Application
1.3.1 Global Psychedelic Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Depressive Disorders
1.3.3 Post-Traumatic Stress Disorders
1.3.4 Substance Abuse Disorders
1.3.5 Obsessive Compulsive Disorders
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Psychedelic Drugs Market Perspective (2018-2029)
2.2 Global Psychedelic Drugs Growth Trends by Region
2.2.1 Psychedelic Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Psychedelic Drugs Historic Market Size by Region (2018-2023)
2.2.3 Psychedelic Drugs Forecasted Market Size by Region (2024-2029)
2.3 Psychedelic Drugs Market Dynamics
2.3.1 Psychedelic Drugs Industry Trends
2.3.2 Psychedelic Drugs Market Drivers
2.3.3 Psychedelic Drugs Market Challenges
2.3.4 Psychedelic Drugs Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Revenue Psychedelic Drugs by Players
3.1.1 Global Psychedelic Drugs Revenue by Players (2018-2023)
3.1.2 Global Psychedelic Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Psychedelic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Psychedelic Drugs, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Psychedelic Drugs Market Concentration Ratio
3.4.1 Global Psychedelic Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Psychedelic Drugs Revenue in 2022
3.5 Global Key Players of Psychedelic Drugs Head office and Area Served
3.6 Global Key Players of Psychedelic Drugs, Product and Application
3.7 Global Key Players of Psychedelic Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 PSYCHEDELIC DRUGS BREAKDOWN DATA BY TYPE
4.1 Global Psychedelic Drugs Historic Market Size by Type (2018-2023)
4.2 Global Psychedelic Drugs Forecasted Market Size by Type (2024-2029)
5 PSYCHEDELIC DRUGS BREAKDOWN DATA BY APPLICATION
5.1 Global Psychedelic Drugs Historic Market Size by Application (2018-2023)
5.2 Global Psychedelic Drugs Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Psychedelic Drugs Market Size (2018-2029)
6.2 North America Psychedelic Drugs Market Size by Type
6.2.1 North America Psychedelic Drugs Market Size by Type (2018-2023)
6.2.2 North America Psychedelic Drugs Market Size by Type (2024-2029)
6.2.3 North America Psychedelic Drugs Market Share by Type (2018-2029)
6.3 North America Psychedelic Drugs Market Size by Application
6.3.1 North America Psychedelic Drugs Market Size by Application (2018-2023)
6.3.2 North America Psychedelic Drugs Market Size by Application (2024-2029)
6.3.3 North America Psychedelic Drugs Market Share by Application (2018-2029)
6.4 North America Psychedelic Drugs Market Size by Country
6.4.1 North America Psychedelic Drugs Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Psychedelic Drugs Market Size by Country (2018-2023)
6.4.3 North America Psychedelic Drugs Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 EUROPE
7.1 Europe Psychedelic Drugs Market Size (2018-2029)
7.2 Europe Psychedelic Drugs Market Size by Type
7.2.1 Europe Psychedelic Drugs Market Size by Type (2018-2023)
7.2.2 Europe Psychedelic Drugs Market Size by Type (2024-2029)
7.2.3 Europe Psychedelic Drugs Market Share by Type (2018-2029)
7.3 Europe Psychedelic Drugs Market Size by Application
7.3.1 Europe Psychedelic Drugs Market Size by Application (2018-2023)
7.3.2 Europe Psychedelic Drugs Market Size by Application (2024-2029)
7.3.3 Europe Psychedelic Drugs Market Share by Application (2018-2029)
7.4 Europe Psychedelic Drugs Market Size by Country
7.4.1 Europe Psychedelic Drugs Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Psychedelic Drugs Market Size by Country (2018-2023)
7.4.3 Europe Psychedelic Drugs Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 CHINA
8.1 China Psychedelic Drugs Market Size (2018-2029)
8.2 China Psychedelic Drugs Market Size by Type
8.2.1 China Psychedelic Drugs Market Size by Type (2018-2023)
8.2.2 China Psychedelic Drugs Market Size by Type (2024-2029)
8.2.3 China Psychedelic Drugs Market Share by Type (2018-2029)
8.3 China Psychedelic Drugs Market Size by Application
8.3.1 China Psychedelic Drugs Market Size by Application (2018-2023)
8.3.2 China Psychedelic Drugs Market Size by Application (2024-2029)
8.3.3 China Psychedelic Drugs Market Share by Application (2018-2029)
9 ASIA (EXCLUDING CHINA)
9.1 Asia Psychedelic Drugs Market Size (2018-2029)
9.2 Asia Psychedelic Drugs Market Size by Type
9.2.1 Asia Psychedelic Drugs Market Size by Type (2018-2023)
9.2.2 Asia Psychedelic Drugs Market Size by Type (2024-2029)
9.2.3 Asia Psychedelic Drugs Market Share by Type (2018-2029)
9.3 Asia Psychedelic Drugs Market Size by Application
9.3.1 Asia Psychedelic Drugs Market Size by Application (2018-2023)
9.3.2 Asia Psychedelic Drugs Market Size by Application (2024-2029)
9.3.3 Asia Psychedelic Drugs Market Share by Application (2018-2029)
9.4 Asia Psychedelic Drugs Market Size by Region
9.4.1 Asia Psychedelic Drugs Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Psychedelic Drugs Market Size by Region (2018-2023)
9.4.3 Asia Psychedelic Drugs Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 MIDDLE EAST, AFRICA, AND LATIN AMERICA
10.1 Middle East, Africa, and Latin America Psychedelic Drugs Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Type
10.2.1 Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Psychedelic Drugs Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Application
10.3.1 Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Psychedelic Drugs Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Country
10.4.1 Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 KEY PLAYERS PROFILES
11.1 COMPASS Pathways PLC
11.1.1 COMPASS Pathways PLC Company Details
11.1.2 COMPASS Pathways PLC Business Overview
11.1.3 COMPASS Pathways PLC Psychedelic Drugs Introduction
11.1.4 COMPASS Pathways PLC Revenue in Psychedelic Drugs Business (2018-2023)
11.1.5 COMPASS Pathways PLC Recent Developments
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Psychedelic Drugs Introduction
11.2.4 Pfizer Revenue in Psychedelic Drugs Business (2018-2023)
11.2.5 Pfizer Recent Developments
11.3 Eli Lilly
11.3.1 Eli Lilly Company Details
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly Psychedelic Drugs Introduction
11.3.4 Eli Lilly Revenue in Psychedelic Drugs Business (2018-2023)
11.3.5 Eli Lilly Recent Developments
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Details
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Psychedelic Drugs Introduction
11.4.4 GlaxoSmithKline Revenue in Psychedelic Drugs Business (2018-2023)
11.4.5 GlaxoSmithKline Recent Developments
11.5 Cybin Inc
11.5.1 Cybin Inc Company Details
11.5.2 Cybin Inc Business Overview
11.5.3 Cybin Inc Psychedelic Drugs Introduction
11.5.4 Cybin Inc Revenue in Psychedelic Drugs Business (2018-2023)
11.5.5 Cybin Inc Recent Developments
11.6 Field Trip Health
11.6.1 Field Trip Health Company Details
11.6.2 Field Trip Health Business Overview
11.6.3 Field Trip Health Psychedelic Drugs Introduction
11.6.4 Field Trip Health Revenue in Psychedelic Drugs Business (2018-2023)
11.6.5 Field Trip Health Recent Developments
11.7 ATAI Life Sciences
11.7.1 ATAI Life Sciences Company Details
11.7.2 ATAI Life Sciences Business Overview
11.7.3 ATAI Life Sciences Psychedelic Drugs Introduction
11.7.4 ATAI Life Sciences Revenue in Psychedelic Drugs Business (2018-2023)
11.7.5 ATAI Life Sciences Recent Developments
11.8 NUMINUS WELLNESS
11.8.1 NUMINUS WELLNESS Company Details
11.8.2 NUMINUS WELLNESS Business Overview
11.8.3 NUMINUS WELLNESS Psychedelic Drugs Introduction
11.8.4 NUMINUS WELLNESS Revenue in Psychedelic Drugs Business (2018-2023)
11.8.5 NUMINUS WELLNESS Recent Developments
11.9 MindMed
11.9.1 MindMed Company Details
11.9.2 MindMed Business Overview
11.9.3 MindMed Psychedelic Drugs Introduction
11.9.4 MindMed Revenue in Psychedelic Drugs Business (2018-2023)
11.9.5 MindMed Recent Developments
11.10 HAVN Life Sciences
11.10.1 HAVN Life Sciences Company Details
11.10.2 HAVN Life Sciences Business Overview
11.10.3 HAVN Life Sciences Psychedelic Drugs Introduction
11.10.4 HAVN Life Sciences Revenue in Psychedelic Drugs Business (2018-2023)
11.10.5 HAVN Life Sciences Recent Developments
11.11 Seelos Therapeutics
11.11.1 Seelos Therapeutics Company Details
11.11.2 Seelos Therapeutics Business Overview
11.11.3 Seelos Therapeutics Psychedelic Drugs Introduction
11.11.4 Seelos Therapeutics Revenue in Psychedelic Drugs Business (2018-2023)
11.11.5 Seelos Therapeutics Recent Developments
11.12 Jannsen
11.12.1 Jannsen Company Details
11.12.2 Jannsen Business Overview
11.12.3 Jannsen Psychedelic Drugs Introduction
11.12.4 Jannsen Revenue in Psychedelic Drugs Business (2018-2023)
11.12.5 Jannsen Recent Developments
11.13 Acadia Pharmaceuticals
11.13.1 Acadia Pharmaceuticals Company Details
11.13.2 Acadia Pharmaceuticals Business Overview
11.13.3 Acadia Pharmaceuticals Psychedelic Drugs Introduction
11.13.4 Acadia Pharmaceuticals Revenue in Psychedelic Drugs Business (2018-2023)
11.13.5 Acadia Pharmaceuticals Recent Developments
11.14 Intellipharmaceutics
11.14.1 Intellipharmaceutics Company Details
11.14.2 Intellipharmaceutics Business Overview
11.14.3 Intellipharmaceutics Psychedelic Drugs Introduction
11.14.4 Intellipharmaceutics Revenue in Psychedelic Drugs Business (2018-2023)
11.14.5 Intellipharmaceutics Recent Developments
11.15 Revive Therapeutics
11.15.1 Revive Therapeutics Company Details
11.15.2 Revive Therapeutics Business Overview
11.15.3 Revive Therapeutics Psychedelic Drugs Introduction
11.15.4 Revive Therapeutics Revenue in Psychedelic Drugs Business (2018-2023)
11.15.5 Revive Therapeutics Recent Developments
11.16 Mydecine Innovations Group
11.16.1 Mydecine Innovations Group Company Details
11.16.2 Mydecine Innovations Group Business Overview
11.16.3 Mydecine Innovations Group Psychedelic Drugs Introduction
11.16.4 Mydecine Innovations Group Revenue in Psychedelic Drugs Business (2018-2023)
11.16.5 Mydecine Innovations Group Recent Developments
11.17 Red Light Holland
11.17.1 Red Light Holland Company Details
11.17.2 Red Light Holland Business Overview
11.17.3 Red Light Holland Psychedelic Drugs Introduction
11.17.4 Red Light Holland Revenue in Psychedelic Drugs Business (2018-2023)
11.17.5 Red Light Holland Recent Developments
11.18 Braxia Scientific
11.18.1 Braxia Scientific Company Details
11.18.2 Braxia Scientific Business Overview
11.18.3 Braxia Scientific Psychedelic Drugs Introduction
11.18.4 Braxia Scientific Revenue in Psychedelic Drugs Business (2018-2023)
11.18.5 Braxia Scientific Recent Developments
11.19 Mind Cure Health
11.19.1 Mind Cure Health Company Details
11.19.2 Mind Cure Health Business Overview
11.19.3 Mind Cure Health Psychedelic Drugs Introduction
11.19.4 Mind Cure Health Revenue in Psychedelic Drugs Business (2018-2023)
11.19.5 Mind Cure Health Recent Developments
11.20 Entheon Biomedical
11.20.1 Entheon Biomedical Company Details
11.20.2 Entheon Biomedical Business Overview
11.20.3 Entheon Biomedical Psychedelic Drugs Introduction
11.20.4 Entheon Biomedical Revenue in Psychedelic Drugs Business (2018-2023)
11.20.5 Entheon Biomedical Recent Developments
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
LIST OF TABLES
Table 1. Global Psychedelic Drugs Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Psilocybin
Table 3. Key Players of LSD
Table 4. Key Players of MDMA
Table 5. Key Players of DMT
Table 6. Key Players of Ketamine
Table 7. Key Players of Others
Table 8. Global Psychedelic Drugs Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 9. Global Psychedelic Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 10. Global Psychedelic Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 11. Global Psychedelic Drugs Market Share by Region (2018-2023)
Table 12. Global Psychedelic Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 13. Global Psychedelic Drugs Market Share by Region (2024-2029)
Table 14. Psychedelic Drugs Market Trends
Table 15. Psychedelic Drugs Market Drivers
Table 16. Psychedelic Drugs Market Challenges
Table 17. Psychedelic Drugs Market Restraints
Table 18. Global Psychedelic Drugs Revenue by Players (2018-2023) & (US$ Million)
Table 19. Global Psychedelic Drugs Revenue Share by Players (2018-2023)
Table 20. Global Top Psychedelic Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Psychedelic Drugs as of 2022)
Table 21. Global Psychedelic Drugs Industry Ranking 2021 VS 2022 VS 2023
Table 22. Global 5 Largest Players Market Share by Psychedelic Drugs Revenue (CR5 and HHI) & (2018-2023)
Table 23. Global Key Players of Psychedelic Drugs, Headquarters and Area Served
Table 24. Global Key Players of Psychedelic Drugs, Product and Application
Table 25. Global Key Players of Psychedelic Drugs, Product and Application
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Psychedelic Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 28. Global Psychedelic Drugs Revenue Market Share by Type (2018-2023)
Table 29. Global Psychedelic Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 30. Global Psychedelic Drugs Revenue Market Share by Type (2024-2029)
Table 31. Global Psychedelic Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 32. Global Psychedelic Drugs Revenue Share by Application (2018-2023)
Table 33. Global Psychedelic Drugs Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 34. Global Psychedelic Drugs Revenue Share by Application (2024-2029)
Table 35. North America Psychedelic Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 36. North America Psychedelic Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 37. North America Psychedelic Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 38. North America Psychedelic Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 39. North America Psychedelic Drugs Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 40. North America Psychedelic Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 41. North America Psychedelic Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 42. Europe Psychedelic Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 43. Europe Psychedelic Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 44. Europe Psychedelic Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 45. Europe Psychedelic Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 46. Europe Psychedelic Drugs Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 47. Europe Psychedelic Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 48. Europe Psychedelic Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 49. China Psychedelic Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 50. China Psychedelic Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 51. China Psychedelic Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 52. China Psychedelic Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 53. Asia Psychedelic Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 54. Asia Psychedelic Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 55. Asia Psychedelic Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 56. Asia Psychedelic Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 57. Asia Psychedelic Drugs Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 58. Asia Psychedelic Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 59. Asia Psychedelic Drugs Market Size by Region (2024-2029) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 64. Middle East, Africa, and Latin America Psychedelic Drugs Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 65. Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 66. Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 67. COMPASS Pathways PLC Company Details
Table 68. COMPASS Pathways PLC Business Overview
Table 69. COMPASS Pathways PLC Psychedelic Drugs Product
Table 70. COMPASS Pathways PLC Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 71. COMPASS Pathways PLC Recent Developments
Table 72. Pfizer Company Details
Table 73. Pfizer Business Overview
Table 74. Pfizer Psychedelic Drugs Product
Table 75. Pfizer Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 76. Pfizer Recent Developments
Table 77. Eli Lilly Company Details
Table 78. Eli Lilly Business Overview
Table 79. Eli Lilly Psychedelic Drugs Product
Table 80. Eli Lilly Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 81. Eli Lilly Recent Developments
Table 82. GlaxoSmithKline Company Details
Table 83. GlaxoSmithKline Business Overview
Table 84. GlaxoSmithKline Psychedelic Drugs Product
Table 85. GlaxoSmithKline Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 86. GlaxoSmithKline Recent Developments
Table 87. Cybin Inc Company Details
Table 88. Cybin Inc Business Overview
Table 89. Cybin Inc Psychedelic Drugs Product
Table 90. Cybin Inc Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 91. Cybin Inc Recent Developments
Table 92. Field Trip Health Company Details
Table 93. Field Trip Health Business Overview
Table 94. Field Trip Health Psychedelic Drugs Product
Table 95. Field Trip Health Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 96. Field Trip Health Recent Developments
Table 97. ATAI Life Sciences Company Details
Table 98. ATAI Life Sciences Business Overview
Table 99. ATAI Life Sciences Psychedelic Drugs Product
Table 100. ATAI Life Sciences Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 101. ATAI Life Sciences Recent Developments
Table 102. NUMINUS WELLNESS Company Details
Table 103. NUMINUS WELLNESS Business Overview
Table 104. NUMINUS WELLNESS Psychedelic Drugs Product
Table 105. NUMINUS WELLNESS Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 106. NUMINUS WELLNESS Recent Developments
Table 107. MindMed Company Details
Table 108. MindMed Business Overview
Table 109. MindMed Psychedelic Drugs Product
Table 110. MindMed Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 111. MindMed Recent Developments
Table 112. HAVN Life Sciences Company Details
Table 113. HAVN Life Sciences Business Overview
Table 114. HAVN Life Sciences Psychedelic Drugs Product
Table 115. HAVN Life Sciences Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 116. HAVN Life Sciences Recent Developments
Table 117. Seelos Therapeutics Company Details
Table 118. Seelos Therapeutics Business Overview
Table 119. Seelos Therapeutics Psychedelic Drugs Product
Table 120. Seelos Therapeutics Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 121. Seelos Therapeutics Recent Developments
Table 122. Jannsen Company Details
Table 123. Jannsen Business Overview
Table 124. Jannsen Psychedelic Drugs Product
Table 125. Jannsen Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 126. Jannsen Recent Developments
Table 127. Acadia Pharmaceuticals Company Details
Table 128. Acadia Pharmaceuticals Business Overview
Table 129. Acadia Pharmaceuticals Psychedelic Drugs Product
Table 130. Acadia Pharmaceuticals Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 131. Acadia Pharmaceuticals Recent Developments
Table 132. Intellipharmaceutics Company Details
Table 133. Intellipharmaceutics Business Overview
Table 134. Intellipharmaceutics Psychedelic Drugs Product
Table 135. Intellipharmaceutics Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 136. Intellipharmaceutics Recent Developments
Table 137. Revive Therapeutics Company Details
Table 138. Revive Therapeutics Business Overview
Table 139. Revive Therapeutics Psychedelic Drugs Product
Table 140. Revive Therapeutics Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 141. Revive Therapeutics Recent Developments
Table 142. Mydecine Innovations Group Company Details
Table 143. Mydecine Innovations Group Business Overview
Table 144. Mydecine Innovations Group Psychedelic Drugs Product
Table 145. Mydecine Innovations Group Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 146. Mydecine Innovations Group Recent Developments
Table 147. Red Light Holland Company Details
Table 148. Red Light Holland Business Overview
Table 149. Red Light Holland Psychedelic Drugs Product
Table 150. Red Light Holland Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 151. Red Light Holland Recent Developments
Table 152. Braxia Scientific Company Details
Table 153. Braxia Scientific Business Overview
Table 154. Braxia Scientific Psychedelic Drugs Product
Table 155. Braxia Scientific Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 156. Braxia Scientific Recent Developments
Table 157. Mind Cure Health Company Details
Table 158. Mind Cure Health Business Overview
Table 159. Mind Cure Health Psychedelic Drugs Product
Table 160. Mind Cure Health Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 161. Mind Cure Health Recent Developments
Table 162. Entheon Biomedical Company Details
Table 163. Entheon Biomedical Business Overview
Table 164. Entheon Biomedical Psychedelic Drugs Product
Table 165. Entheon Biomedical Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 166. Entheon Biomedical Recent Developments
Table 167. Research Programs/Design for This Report
Table 168. Key Data Information from Secondary Sources
Table 169. Key Data Information from Primary Sources
Table 1. Global Psychedelic Drugs Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Psilocybin
Table 3. Key Players of LSD
Table 4. Key Players of MDMA
Table 5. Key Players of DMT
Table 6. Key Players of Ketamine
Table 7. Key Players of Others
Table 8. Global Psychedelic Drugs Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 9. Global Psychedelic Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 10. Global Psychedelic Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 11. Global Psychedelic Drugs Market Share by Region (2018-2023)
Table 12. Global Psychedelic Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 13. Global Psychedelic Drugs Market Share by Region (2024-2029)
Table 14. Psychedelic Drugs Market Trends
Table 15. Psychedelic Drugs Market Drivers
Table 16. Psychedelic Drugs Market Challenges
Table 17. Psychedelic Drugs Market Restraints
Table 18. Global Psychedelic Drugs Revenue by Players (2018-2023) & (US$ Million)
Table 19. Global Psychedelic Drugs Revenue Share by Players (2018-2023)
Table 20. Global Top Psychedelic Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Psychedelic Drugs as of 2022)
Table 21. Global Psychedelic Drugs Industry Ranking 2021 VS 2022 VS 2023
Table 22. Global 5 Largest Players Market Share by Psychedelic Drugs Revenue (CR5 and HHI) & (2018-2023)
Table 23. Global Key Players of Psychedelic Drugs, Headquarters and Area Served
Table 24. Global Key Players of Psychedelic Drugs, Product and Application
Table 25. Global Key Players of Psychedelic Drugs, Product and Application
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Psychedelic Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 28. Global Psychedelic Drugs Revenue Market Share by Type (2018-2023)
Table 29. Global Psychedelic Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 30. Global Psychedelic Drugs Revenue Market Share by Type (2024-2029)
Table 31. Global Psychedelic Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 32. Global Psychedelic Drugs Revenue Share by Application (2018-2023)
Table 33. Global Psychedelic Drugs Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 34. Global Psychedelic Drugs Revenue Share by Application (2024-2029)
Table 35. North America Psychedelic Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 36. North America Psychedelic Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 37. North America Psychedelic Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 38. North America Psychedelic Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 39. North America Psychedelic Drugs Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 40. North America Psychedelic Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 41. North America Psychedelic Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 42. Europe Psychedelic Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 43. Europe Psychedelic Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 44. Europe Psychedelic Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 45. Europe Psychedelic Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 46. Europe Psychedelic Drugs Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 47. Europe Psychedelic Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 48. Europe Psychedelic Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 49. China Psychedelic Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 50. China Psychedelic Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 51. China Psychedelic Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 52. China Psychedelic Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 53. Asia Psychedelic Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 54. Asia Psychedelic Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 55. Asia Psychedelic Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 56. Asia Psychedelic Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 57. Asia Psychedelic Drugs Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 58. Asia Psychedelic Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 59. Asia Psychedelic Drugs Market Size by Region (2024-2029) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 64. Middle East, Africa, and Latin America Psychedelic Drugs Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 65. Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 66. Middle East, Africa, and Latin America Psychedelic Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 67. COMPASS Pathways PLC Company Details
Table 68. COMPASS Pathways PLC Business Overview
Table 69. COMPASS Pathways PLC Psychedelic Drugs Product
Table 70. COMPASS Pathways PLC Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 71. COMPASS Pathways PLC Recent Developments
Table 72. Pfizer Company Details
Table 73. Pfizer Business Overview
Table 74. Pfizer Psychedelic Drugs Product
Table 75. Pfizer Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 76. Pfizer Recent Developments
Table 77. Eli Lilly Company Details
Table 78. Eli Lilly Business Overview
Table 79. Eli Lilly Psychedelic Drugs Product
Table 80. Eli Lilly Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 81. Eli Lilly Recent Developments
Table 82. GlaxoSmithKline Company Details
Table 83. GlaxoSmithKline Business Overview
Table 84. GlaxoSmithKline Psychedelic Drugs Product
Table 85. GlaxoSmithKline Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 86. GlaxoSmithKline Recent Developments
Table 87. Cybin Inc Company Details
Table 88. Cybin Inc Business Overview
Table 89. Cybin Inc Psychedelic Drugs Product
Table 90. Cybin Inc Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 91. Cybin Inc Recent Developments
Table 92. Field Trip Health Company Details
Table 93. Field Trip Health Business Overview
Table 94. Field Trip Health Psychedelic Drugs Product
Table 95. Field Trip Health Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 96. Field Trip Health Recent Developments
Table 97. ATAI Life Sciences Company Details
Table 98. ATAI Life Sciences Business Overview
Table 99. ATAI Life Sciences Psychedelic Drugs Product
Table 100. ATAI Life Sciences Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 101. ATAI Life Sciences Recent Developments
Table 102. NUMINUS WELLNESS Company Details
Table 103. NUMINUS WELLNESS Business Overview
Table 104. NUMINUS WELLNESS Psychedelic Drugs Product
Table 105. NUMINUS WELLNESS Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 106. NUMINUS WELLNESS Recent Developments
Table 107. MindMed Company Details
Table 108. MindMed Business Overview
Table 109. MindMed Psychedelic Drugs Product
Table 110. MindMed Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 111. MindMed Recent Developments
Table 112. HAVN Life Sciences Company Details
Table 113. HAVN Life Sciences Business Overview
Table 114. HAVN Life Sciences Psychedelic Drugs Product
Table 115. HAVN Life Sciences Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 116. HAVN Life Sciences Recent Developments
Table 117. Seelos Therapeutics Company Details
Table 118. Seelos Therapeutics Business Overview
Table 119. Seelos Therapeutics Psychedelic Drugs Product
Table 120. Seelos Therapeutics Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 121. Seelos Therapeutics Recent Developments
Table 122. Jannsen Company Details
Table 123. Jannsen Business Overview
Table 124. Jannsen Psychedelic Drugs Product
Table 125. Jannsen Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 126. Jannsen Recent Developments
Table 127. Acadia Pharmaceuticals Company Details
Table 128. Acadia Pharmaceuticals Business Overview
Table 129. Acadia Pharmaceuticals Psychedelic Drugs Product
Table 130. Acadia Pharmaceuticals Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 131. Acadia Pharmaceuticals Recent Developments
Table 132. Intellipharmaceutics Company Details
Table 133. Intellipharmaceutics Business Overview
Table 134. Intellipharmaceutics Psychedelic Drugs Product
Table 135. Intellipharmaceutics Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 136. Intellipharmaceutics Recent Developments
Table 137. Revive Therapeutics Company Details
Table 138. Revive Therapeutics Business Overview
Table 139. Revive Therapeutics Psychedelic Drugs Product
Table 140. Revive Therapeutics Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 141. Revive Therapeutics Recent Developments
Table 142. Mydecine Innovations Group Company Details
Table 143. Mydecine Innovations Group Business Overview
Table 144. Mydecine Innovations Group Psychedelic Drugs Product
Table 145. Mydecine Innovations Group Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 146. Mydecine Innovations Group Recent Developments
Table 147. Red Light Holland Company Details
Table 148. Red Light Holland Business Overview
Table 149. Red Light Holland Psychedelic Drugs Product
Table 150. Red Light Holland Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 151. Red Light Holland Recent Developments
Table 152. Braxia Scientific Company Details
Table 153. Braxia Scientific Business Overview
Table 154. Braxia Scientific Psychedelic Drugs Product
Table 155. Braxia Scientific Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 156. Braxia Scientific Recent Developments
Table 157. Mind Cure Health Company Details
Table 158. Mind Cure Health Business Overview
Table 159. Mind Cure Health Psychedelic Drugs Product
Table 160. Mind Cure Health Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 161. Mind Cure Health Recent Developments
Table 162. Entheon Biomedical Company Details
Table 163. Entheon Biomedical Business Overview
Table 164. Entheon Biomedical Psychedelic Drugs Product
Table 165. Entheon Biomedical Revenue in Psychedelic Drugs Business (2018-2023) & (US$ Million)
Table 166. Entheon Biomedical Recent Developments
Table 167. Research Programs/Design for This Report
Table 168. Key Data Information from Secondary Sources
Table 169. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Psychedelic Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Psychedelic Drugs Market Share by Type: 2022 VS 2029
Figure 3. Psilocybin Features
Figure 4. LSD Features
Figure 5. MDMA Features
Figure 6. DMT Features
Figure 7. Ketamine Features
Figure 8. Others Features
Figure 9. Global Psychedelic Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 10. Global Psychedelic Drugs Market Share by Application: 2022 VS 2029
Figure 11. Depressive Disorders Case Studies
Figure 12. Post-Traumatic Stress Disorders Case Studies
Figure 13. Substance Abuse Disorders Case Studies
Figure 14. Obsessive Compulsive Disorders Case Studies
Figure 15. Others Case Studies
Figure 16. Psychedelic Drugs Report Years Considered
Figure 17. Global Psychedelic Drugs Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 18. Global Psychedelic Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 19. Global Psychedelic Drugs Market Share by Region: 2022 VS 2029
Figure 20. Global Psychedelic Drugs Market Share by Players in 2022
Figure 21. Global Top Psychedelic Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Psychedelic Drugs as of 2022)
Figure 22. The Top 10 and 5 Players Market Share by Psychedelic Drugs Revenue in 2022
Figure 23. North America Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. North America Psychedelic Drugs Market Share by Type (2018-2029)
Figure 25. North America Psychedelic Drugs Market Share by Application (2018-2029)
Figure 26. North America Psychedelic Drugs Market Share by Country (2018-2029)
Figure 27. United States Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Canada Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Europe Psychedelic Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 30. Europe Psychedelic Drugs Market Share by Type (2018-2029)
Figure 31. Europe Psychedelic Drugs Market Share by Application (2018-2029)
Figure 32. Europe Psychedelic Drugs Market Share by Country (2018-2029)
Figure 33. Germany Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. France Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. U.K. Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Italy Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Russia Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Nordic Countries Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. China Psychedelic Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 40. China Psychedelic Drugs Market Share by Type (2018-2029)
Figure 41. China Psychedelic Drugs Market Share by Application (2018-2029)
Figure 42. Asia Psychedelic Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 43. Asia Psychedelic Drugs Market Share by Type (2018-2029)
Figure 44. Asia Psychedelic Drugs Market Share by Application (2018-2029)
Figure 45. Asia Psychedelic Drugs Market Share by Region (2018-2029)
Figure 46. Japan Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. South Korea Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. China Taiwan Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Southeast Asia Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 50. India Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 51. Australia Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. Middle East, Africa, and Latin America Psychedelic Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 53. Middle East, Africa, and Latin America Psychedelic Drugs Market Share by Type (2018-2029)
Figure 54. Middle East, Africa, and Latin America Psychedelic Drugs Market Share by Application (2018-2029)
Figure 55. Middle East, Africa, and Latin America Psychedelic Drugs Market Share by Country (2018-2029)
Figure 56. Brazil Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. Mexico Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. Turkey Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 59. Saudi Arabia Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 60. Israel Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 61. GCC Countries Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 62. COMPASS Pathways PLC Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 63. Pfizer Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 64. Eli Lilly Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 65. GlaxoSmithKline Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 66. Cybin Inc Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 67. Field Trip Health Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 68. ATAI Life Sciences Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 69. NUMINUS WELLNESS Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 70. MindMed Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 71. HAVN Life Sciences Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 72. Seelos Therapeutics Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 73. Jannsen Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 74. Acadia Pharmaceuticals Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 75. Intellipharmaceutics Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 76. Revive Therapeutics Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 77. Mydecine Innovations Group Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 78. Red Light Holland Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 79. Braxia Scientific Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 80. Mind Cure Health Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 81. Entheon Biomedical Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 82. Bottom-up and Top-down Approaches for This Report
Figure 83. Data Triangulation
Figure 84. Key Executives Interviewed
Figure 1. Global Psychedelic Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Psychedelic Drugs Market Share by Type: 2022 VS 2029
Figure 3. Psilocybin Features
Figure 4. LSD Features
Figure 5. MDMA Features
Figure 6. DMT Features
Figure 7. Ketamine Features
Figure 8. Others Features
Figure 9. Global Psychedelic Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 10. Global Psychedelic Drugs Market Share by Application: 2022 VS 2029
Figure 11. Depressive Disorders Case Studies
Figure 12. Post-Traumatic Stress Disorders Case Studies
Figure 13. Substance Abuse Disorders Case Studies
Figure 14. Obsessive Compulsive Disorders Case Studies
Figure 15. Others Case Studies
Figure 16. Psychedelic Drugs Report Years Considered
Figure 17. Global Psychedelic Drugs Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 18. Global Psychedelic Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 19. Global Psychedelic Drugs Market Share by Region: 2022 VS 2029
Figure 20. Global Psychedelic Drugs Market Share by Players in 2022
Figure 21. Global Top Psychedelic Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Psychedelic Drugs as of 2022)
Figure 22. The Top 10 and 5 Players Market Share by Psychedelic Drugs Revenue in 2022
Figure 23. North America Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. North America Psychedelic Drugs Market Share by Type (2018-2029)
Figure 25. North America Psychedelic Drugs Market Share by Application (2018-2029)
Figure 26. North America Psychedelic Drugs Market Share by Country (2018-2029)
Figure 27. United States Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Canada Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Europe Psychedelic Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 30. Europe Psychedelic Drugs Market Share by Type (2018-2029)
Figure 31. Europe Psychedelic Drugs Market Share by Application (2018-2029)
Figure 32. Europe Psychedelic Drugs Market Share by Country (2018-2029)
Figure 33. Germany Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. France Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. U.K. Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Italy Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Russia Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Nordic Countries Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. China Psychedelic Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 40. China Psychedelic Drugs Market Share by Type (2018-2029)
Figure 41. China Psychedelic Drugs Market Share by Application (2018-2029)
Figure 42. Asia Psychedelic Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 43. Asia Psychedelic Drugs Market Share by Type (2018-2029)
Figure 44. Asia Psychedelic Drugs Market Share by Application (2018-2029)
Figure 45. Asia Psychedelic Drugs Market Share by Region (2018-2029)
Figure 46. Japan Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. South Korea Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. China Taiwan Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Southeast Asia Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 50. India Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 51. Australia Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. Middle East, Africa, and Latin America Psychedelic Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 53. Middle East, Africa, and Latin America Psychedelic Drugs Market Share by Type (2018-2029)
Figure 54. Middle East, Africa, and Latin America Psychedelic Drugs Market Share by Application (2018-2029)
Figure 55. Middle East, Africa, and Latin America Psychedelic Drugs Market Share by Country (2018-2029)
Figure 56. Brazil Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. Mexico Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. Turkey Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 59. Saudi Arabia Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 60. Israel Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 61. GCC Countries Psychedelic Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 62. COMPASS Pathways PLC Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 63. Pfizer Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 64. Eli Lilly Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 65. GlaxoSmithKline Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 66. Cybin Inc Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 67. Field Trip Health Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 68. ATAI Life Sciences Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 69. NUMINUS WELLNESS Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 70. MindMed Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 71. HAVN Life Sciences Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 72. Seelos Therapeutics Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 73. Jannsen Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 74. Acadia Pharmaceuticals Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 75. Intellipharmaceutics Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 76. Revive Therapeutics Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 77. Mydecine Innovations Group Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 78. Red Light Holland Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 79. Braxia Scientific Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 80. Mind Cure Health Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 81. Entheon Biomedical Revenue Growth Rate in Psychedelic Drugs Business (2018-2023)
Figure 82. Bottom-up and Top-down Approaches for This Report
Figure 83. Data Triangulation
Figure 84. Key Executives Interviewed
